CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure
CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure of$25.1 million. Net income for 1994 should be $2.3 million, versusa loss of $2.9 million in 1993.
Imatron has enjoyed strong sales of its C-150 Ultrafast CTscanner in recent months. Imatron received an order in Decemberfor 10 C-150 units from Imatron Japan in a transaction worth $16million (SCAN 12/28/94). Revenue from that sale will registerin the company's 1995 and 1996 fiscal years.
Imatron's backlog is at its highest level since the companywas formed in 1983, president and CEO Lewis Meyer said. The backlogshould help the firm register revenues of over $40 million in1995.
This year Imatron will embark on a major expansion of its HeartScanImaging clinics, which provide coronary artery screening directlyto the public (SCAN 4/6/94). Imatron plans to open clinics inSeattle, Houston and Washington, DC.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.